United Therapeutics (UTHR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 26, 2024--Please replace the photo for release dated April 24, 2024 with the accompanying corrected photo.
Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.